Researchers funded by the National Institutes of Health have discovered how a defect in a single master gene disrupts the process by which several genes interact to create myelin, a fatty coating that covers nerve cells and increases the speed and reliability of their electrical signals
Intravenous delivery of an approved clot-busting drug remains the most beneficial proven intervention for ischemic stroke, according to updated American Heart Association/American Stroke Association guidelines published in Stroke: Journal of the American Heart Association.
Researchers have called for a national database to be set up to identify major complications arising from epidural pain relief after a small number of serious problems were identified during a six-year UK study, according to the April issue of Anaesthesia.
In the April 1st issue of Genes & Development, Dr. Bruce Spiegelman (Dana Farber Cancer Institute) and colleagues identify a key genetic component of and possible therapeutic target for Duchenne muscular dystrophy.
The Food and Drug Administration (FDA) has requested that Novartis Pharmaceuticals Corporation of East Hanover, New Jersey, voluntarily discontinue marketing of Zelnorm (tegaserod) based on the recently identified finding of an increased risk of serious cardiovascular adverse events (heart problems) associated with use of the drug.
Health benefits associated with physical activity during leisure time are widely recognized, but it is not known if leisure-time physical activity decreases the risk of work-related repetitive strain injury (RSI).
Berlex, Microsoft, and the National Multiple Sclerosis Society Embark on Landmark Collaboration to Help People with MS Maintain Their Health and Stay Connected.
A measure of cardiac regulation called “heart rate variability” (HRV) appears to be linked to self regulation. HRV was considerably higher when people were working to resist temptation.
A new photographic exhibit, called ?The Image of MS? has been unveiled at the Ara Pacis Museum in Rome to dispel myths about multiple sclerosis (MS), challenge public perceptions about the disease, and encourage those with symptoms to seek treatment as early as possible.
The U.S. Food and Drug Administration (FDA) approved Soliris (eculizumab), the first product for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a rare type of blood disorder that can lead to disability and premature death. Soliris is classified as an Orphan Drug and is a new molecular entity containing an ingredient not previously marketed in the United States.